Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Associations between short-term exposure of ambient particulate matter and hemodialysis patients death: A nationwide, longitudinal case-control study in China.
Lou X, Zhang P, Shi N, Ding Z, Xu Z, Liu B, Hu W, Yan T, Wang J, Liu L, Zha Y, Wang J, Chen W, Xu C, Xu J, Jiang H, Ma H, Yuan W, Wang C, Liao Y, Wang D, Yao L, Chen M, Li G, Li Y, Wang P, Li X, Lu C, Tang W, Wan J, Li R, Xiao X, Zhang C, Jiao J, Zhang W, Yuan J, Lan L, Li J, Zhang P, Zheng W, Chen J. Lou X, et al. Among authors: yan t. Sci Total Environ. 2022 Dec 15;852:158215. doi: 10.1016/j.scitotenv.2022.158215. Epub 2022 Aug 24. Sci Total Environ. 2022. PMID: 36028020
DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients.
Ni Z, Lu R, Xu X, Bian X, Zhou Z, Yang J, Luo Q, Chen M, Chen C, Sun X, Yu L, He Q, Jiang H, Yuan W, Li Y, Zhou R, Wang J, Zhang X, Zuo L, Meng X, Chang Z, Zhao J, Wessman P, Xiang P; DIALIZE China Study Group. Ni Z, et al. Clin Ther. 2023 Jul;45(7):633-642. doi: 10.1016/j.clinthera.2023.04.014. Epub 2023 Jun 27. Clin Ther. 2023. PMID: 37385905 Free article. Clinical Trial.
Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial.
Zhang P, Jiang Y, Xu C, Zhou L, Zheng H, Xie D, Guo M, Huang X, Lu G, Jiang H, Qiu H, Liu B, Li S, Chen Q, Xia Y, Sun B, Yang X, Zhang S, Du S, Sun M, Chen M, Zhong A, Wang X, Zhao Z, Zhou H, Li G, Ren Y, Luo Q, Yang A, Luo P, Tang S, Xu C, Wang Q, Wang X, Yan T, He W, Qin S, Zhang W, Lv L, Wang C, Liu H, Li J, Wu Q, Pan C, Li C, He L, Chen J. Zhang P, et al. Among authors: yan t. EClinicalMedicine. 2023 Oct 28;65:102273. doi: 10.1016/j.eclinm.2023.102273. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37954906 Free PMC article.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
4,201 results